Literature DB >> 15750656

Enantiomeric cannabidiol derivatives: synthesis and binding to cannabinoid receptors.

Lumír O Hanus1, Susanna Tchilibon, Datta E Ponde, Aviva Breuer, Ester Fride, Raphael Mechoulam.   

Abstract

(-)-Cannabidiol (CBD) is a major, non psychotropic constituent of cannabis. It has been shown to cause numerous physiological effects of therapeutic importance. We have reported that CBD derivatives in both enantiomeric series are of pharmaceutical interest. Here we describe the syntheses of the major CBD metabolites, (-)-7-hydroxy-CBD and (-)-CBD-7-oic acid and their dimethylheptyl (DMH) homologs, as well as of the corresponding compounds in the enantiomeric (+)-CBD series. The starting materials were the respective CBD enantiomers and their DMH homologs. The binding of these compounds to the CB(1) and CB(2) cannabinoid receptors are compared. Surprisingly, contrary to the compounds in the (-) series, which do not bind to the receptors, most of the derivatives in the (+) series bind to the CB(1) receptor in the low nanomole range. Some of these compounds also bind weakly to the CB(2) receptor.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15750656     DOI: 10.1039/b416943c

Source DB:  PubMed          Journal:  Org Biomol Chem        ISSN: 1477-0520            Impact factor:   3.876


  17 in total

Review 1.  Cannabidiol regulation of emotion and emotional memory processing: relevance for treating anxiety-related and substance abuse disorders.

Authors:  Jonathan L C Lee; Leandro J Bertoglio; Francisco S Guimarães; Carl W Stevenson
Journal:  Br J Pharmacol       Date:  2017-03-09       Impact factor: 8.739

2.  Fatty acid amide hydrolase deficiency limits early pregnancy events.

Authors:  Haibin Wang; Huirong Xie; Yong Guo; Hao Zhang; Toshifumi Takahashi; Philip J Kingsley; Lawrence J Marnett; Sanjoy K Das; Benjamin F Cravatt; Sudhansu K Dey
Journal:  J Clin Invest       Date:  2006-08       Impact factor: 14.808

Review 3.  A marijuana-drug interaction primer: Precipitants, pharmacology, and pharmacokinetics.

Authors:  Emily J Cox; Neha Maharao; Gabriela Patilea-Vrana; Jashvant D Unadkat; Allan E Rettie; Jeannine S McCune; Mary F Paine
Journal:  Pharmacol Ther       Date:  2019-05-07       Impact factor: 12.310

4.  Using (+)-Carvone to access novel derivatives of (+)-ent-Cannabidiol: the first asymmetric syntheses of (+)-ent-CBDP and (+)-ent-CBDV.

Authors:  Alexandra E Golliher; Antonio J Tenorio; Nina O Dimauro; Nicolas R Mairata; F Omar Holguin; William Maio
Journal:  Tetrahedron Lett       Date:  2021-02-05       Impact factor: 2.415

5.  Synthesis of (+)-didemniserinolipid B: application of a 2-allyl-4-fluorophenyl auxiliary for relay ring-closing metathesis.

Authors:  Christopher C Marvin; Eric A Voight; Judy M Suh; Christopher L Paradise; Steven D Burke
Journal:  J Org Chem       Date:  2008-09-24       Impact factor: 4.354

Review 6.  The Essential Medicinal Chemistry of Cannabidiol (CBD).

Authors:  Kathryn M Nelson; Jonathan Bisson; Gurpreet Singh; James G Graham; Shao-Nong Chen; J Brent Friesen; Jayme L Dahlin; Matthias Niemitz; Michael A Walters; Guido F Pauli
Journal:  J Med Chem       Date:  2020-09-10       Impact factor: 7.446

Review 7.  The cannabinoid acids, analogs and endogenous counterparts.

Authors:  Sumner H Burstein
Journal:  Bioorg Med Chem       Date:  2014-04-01       Impact factor: 3.641

8.  Chirality in Cannabinoid Research.

Authors:  Crist N Filer
Journal:  Cannabis Cannabinoid Res       Date:  2021-02-12

Review 9.  Human Metabolites of Cannabidiol: A Review on Their Formation, Biological Activity, and Relevance in Therapy.

Authors:  István Ujváry; Lumír Hanuš
Journal:  Cannabis Cannabinoid Res       Date:  2016-03-01

10.  Binding and Signaling Studies Disclose a Potential Allosteric Site for Cannabidiol in Cannabinoid CB2 Receptors.

Authors:  Eva Martínez-Pinilla; Katia Varani; Irene Reyes-Resina; Edgar Angelats; Fabrizio Vincenzi; Carlos Ferreiro-Vera; Julen Oyarzabal; Enric I Canela; José L Lanciego; Xavier Nadal; Gemma Navarro; Pier Andrea Borea; Rafael Franco
Journal:  Front Pharmacol       Date:  2017-10-23       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.